R A Johnson

To participate in the conference call, dial 888-256-9154 (and confirmation code # 9676495) approximately 5 to 10 minutes prior to the scheduled start time. If you are unable to participate, a digital replay of the call will be available from Monday, August 4, from 7:30 p.m. ET until midnight on Monday, August 18, by dialing 888-203-1112 and using confirmation code # 9676495.

The live broadcast of PhotoMedex, Inc.'s quarterly conference call will be available online by going to www.photomedex.com and clicking on the link to Investor Relations, and at www.streetevents.com. The online replay will be available shortly after the call at those sites.

About PhotoMedex:

PhotoMedex provides contract medical procedures to hospitals, surgi-centers and doctors' offices, offering a wide range of products and services across multiple specialty areas, including dermatology, urology, gynecology, orthopedics, and other surgical specialties. The Company is a leader in the development, manufacturing and marketing of medical laser products and services. In addition as a result of the merger with ProCyte, PhotoMedex now develops and markets products based on its patented, clinically proven Copper Peptide technology for skin health, hair care and wound care. The Company sells directly to dermatologists, plastic and cosmetic surgeons, spas and salons and through licenses with strategic partners into the consumer market, including a long-term worldwide license agreement with Neutrogena(R), a Johnson & Johnson company. ProCyte brands include Neova(R), Ti-Silc(R), VitalCopper(R), Simple Solutions(R) and AquaSante(R).

Some portions of the conference call, particularly those describing PhotoMedex' strategies, operating expense reductions and business plans, will contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While PhotoMedex is working to achieve those goals, actual results could differ materially from those projected in the forward-looking statements as a result of a number of factors, including difficulties in marketing its products and services, need for capital, competition from other companies and other factors, any of which could have an adverse effect on the business plans of PhotoMedex, its reputation in the industry or its results. In light of significant uncertainties inherent in forward-looking statements included herein and in the conference call, the inclusion of such information in the conference call should not be regarded as a representation by PhotoMedex or its subsidiaries that the forward looking statements will be achieved.

SOURCE: PhotoMedex, Inc.

PhotoMedex, Inc.
Dennis McGrath, CFO, 215-619-3287
info@photomedex.com
or
Investor Contacts:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz, 212-838-3777
Kgolodetz@lhai.com
Bruce Voss, 310-691-7100
Bvoss@lhai.com

Omnilux products deliver pure, optimized, narrowband light via a matrix of LEDs positioned to deliver light uniformly to the treatment area and include:

-- Omnilux Blue(TM), for the treatment of acne and actinic keratosis.

-- Omnilux Plus(TM), for the treatment of wound healing and skin rejuvenation.

-- Omnilux Revive(TM), which is used for skin rejuvenation, or in combination with Omnilux Blue for the treatment of acne or with Omnilux Plus for wound healing.

"Photo Therapeutics products will complement our current product lines and expand our product offering," said Jeff O'Donnell, president and CEO of PhotoMedex. "With our established sales force, we are well positioned to immediately and aggressively market these new products."

R. Rox Anderson, Professor at Harvard Medical School, Adjunct Professor at MIT and Director of the Wellman Center for Photomedicine at Massachusetts General Hospital, added, "PhotoMedex is poised for the future and uniquely qualified to lead the way in this rapidly developing field."

PhotoMedex and Photo Therapeutics products are available directly from PhotoMedex. For more information, visit www.photomedex.com or www.phototherapeutics.com.

About the proposed Photo Therapeutics Acquisition

On August 4, 2008, PhotoMedex, Inc. announced the signing of a definitive purchase agreement to acquire Photo Therapeutics Limited. The proposed acquisition is expected to close in the fourth quarter of 2008.

About Photo Therapeutics

Photo Therapeutics is a developer and provider of non-laser light devices and associated skin care products for the treatment of a range of clinical and aesthetic dermatological conditions. The company operates out of three primary business segments: Professional Devices, Home Use Devices and Skin Care Consumables. The company has a large professional installed base in physician offices, spas and salons. Photo Therapeutics' Omnilux and Lumiere product platforms have generated significant brand equity among professionals and end users given their proven efficacy, ease of use and noninvasive, pain-free regimes. The company's systems treat a wide range of dermatological conditions including acne, photodamage, skin rejuvenation, psoriasis, post-surgery wound healing and non-melanoma skin cancer.

LED technology is based on photo biomodulation and dynamics rather than photo-thermolysis. Photo Therapeutics has recently developed the Omnilux Clear-U and Omnilux New-U, two OTC consumer products addressing the acne and skin rejuvenation markets. The company's home-use products are designed to deliver the same clinical results as their well established professional products. To augment the effects of the Omnilux OTC product line, Photo Therapeutics provides a diverse line of photoceuticals, which generate incremental recurring revenue per end user. Photo Therapeutics' LED technology is protected by 18 patents and 20 applications, which the company believes will restrict other parties from developing similar products.

About PhotoMedex

PhotoMedex offers a wide range of products and services across multiple specialty areas, including dermatology, urology, gynecology, orthopedics and other surgical specialties. PhotoMedex is a leader in the development, manufacturing and marketing of medical laser products and services. PhotoMedex also develops and markets products based on its patented, clinically proven Copper Peptide technology for skin health, hair care and wound care. PhotoMedex sells directly to dermatologists, plastic and cosmetic surgeons, spas and salons and through licenses with strategic partners into the consumer market, including a long-term worldwide license agreement with Neutrogena(R), a Johnson & Johnson company. ProCyte brands include Neova(R), Ti-Silc(R), VitalCopper(R), Simple Solutions(R) and AquaSante(R).

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on managements' current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The forward-looking statements contained in this release include statements about future financial and operating results of Photo Therapeutics Limited and Photo Therapeutics, Inc. and PhotoMedex, Inc. ("PhotoMedex"), the proposed acquisition of Photo Therapeutics Limited and Photo Therapeutics, Inc. by PhotoMedex (the "Proposed Acquisition").

The following risks and factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: risk that the Proposed Acquisition and the Proposed Financing will not be consummated or will not be consummated during the fourth quarter of 2008; risk that Photo Therapeutics' business may not be integrated successfully with that of PhotoMedex; that there will be substantial costs related to the Proposed Acquisition and the Proposed Financing; risk of subsequent default and forced repayment under the convertible notes to be issued in the Proposed Financing if any breach occurs related to these convertible notes; failure to receive the stockholder approvals described above related to the Proposed Acquisition and the Proposed Financing; risks relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on strategic partners, ability to obtain financing, competitive products and other risks identified in PhotoMedex's filings with Securities and Exchange Commission (the "SEC"). PhotoMedex is under no obligation to (and expressly disclaims any such obligation to) update or alter these forward-looking statements, whether as a result of new information, future events or otherwise.

In connection with seeking stockholder approval of the Proposed Financing, PhotoMedex intends to file proxy materials and other relevant documents with the SEC. PhotoMedex's stockholders are urged to read the proxy statement (and any other relevant documents filed) with the SEC when they become available, because they will contain important information about the Proposed Financing. PhotoMedex will mail the definitive proxy statement to its stockholders, who may also obtain free copies of the final proxy statement, as well as PhotoMedex's other filings, without charge, at the SEC's Web site (www.sec.gov) when they become available. Copies of the filings may also be obtained without charge from the Company by directing a request to: 147 Keystone Drive, Montgomeryville, Pennsylvania, 18936, Attention: General Counsel.

The Company's directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from stockholders in respect of the Proposed Financing. Information regarding PhotoMedex's directors and executive officers is available in the Company's 2007 Annual Report on Form 10-K, filed with the SEC on March 17, 2008, as amended by the Company's annual report on Form 10-K/A as filed with the SEC on May 8, 2008. Additional information regarding the interests of such potential participants will be included in the proxy statement and the other relevant documents filed with the SEC when they become available.

SOURCE: PhotoMedex, Inc.

Lippert/Heilshorn & Associates, Inc. 
Kim Sutton Golodetz (investors) 
212-838-3777 
Kgolodetz@lhai.com 
or 
Bruce Voss 
310-691-7100 
Bvoss@lhai.com 
or 
PhotoMedex, Inc. 
Dennis McGrath, CFO 
215-619-3287 
info@photomedex.com

N.V. Perricone M.D. Cosmeceuticals(R) has introduced LIGHT Renewal(TM) treatment to the prestige beauty market. This treatment was developed in conjunction with Photo Therapeutics and combines PTL's Omnilux technology with Dr. Perricone's Nourishing Milky Cleanser and Serum prep to ensure the skin is properly prepared and ready to receive the benefits of this light technology in a dermatological-grade unit that softens fine lines and wrinkles, while improving the appearance of the skin's tone, texture and firmness. Two clinical trials -- one lasting 12 weeks, one lasting nine weeks -- showed effectiveness in rejuvenating skin and reducing fine lines and peri-orbital wrinkles.

"We are excited to be joining forces with Perricone MD Cosmeceuticals, one of the most reputable and fastest growing skin care lines in the world," said Sue D'Arcy, Chief Executive Officer of Photo Therapeutics. "We believe there is a dynamic synergy between our LED Light Therapy technology and Perricone MD Cosmeceuticals that will deliver exceptional results." Perricone skincare products are sold in many high-end skincare outlets such as Sephora, Nordstrom and Bloomingdale's.

Additionally, Photo Therapeutics is taking final steps to introduce its Omnilux New-U(TM) to the home-use market. This FDA-cleared, hand-held device is being made available in a major retailer's outlets across the country.

Photo Therapeutics has announced its intent to be acquired by PhotoMedex, Inc., leaders in medical laser treatments for psoriasis and other skin diseases and marketers of skincare products to dermatologists. This union is expected to spur further investment in the research, development and marketing of Photo Therapeutics' LED and light-based therapies under PhotoMedex to complement therapies in the medical, beauty and cosmetic fields. Ms. D'Arcy stated: "It makes perfect sense to team up with PhotoMedex. Working together, we can answer the demand in this emerging market."

About the Proposed Photo Therapeutics Acquisition

On August 4, 2008 Photo Therapeutics and PhotoMedex signed a definitive agreement for PhotoMedex to acquire Photo Therapeutics. The proposed acquisition is expected to close in the fourth quarter of 2008 and is expected to be funded through an investment of convertible debt provided by a third-party investment fund. PhotoMedex will seek approval from its stockholders for the investment; the shareholders of Photo Therapeutics have already ratified the definitive agreement and the terms proposed for financing the acquisition.

About Photo Therapeutics

Photo Therapeutics is a developer and provider of non-laser light devices and associated skin care products for the treatment of a range of clinical and aesthetic dermatological conditions. The company operates out of three primary business segments: Professional Devices, Home Use Devices and Skin Care Consumables. The company has a large professional installed base in physician offices, spas and salons. Photo Therapeutics' Omnilux and Lumiere product platforms have generated significant brand equity among professionals and end users given their proven efficacy, ease of use and noninvasive, pain-free regimes. The company's systems treat a wide range of dermatological conditions including acne, photodamage, skin rejuvenation, psoriasis, post-surgery wound healing and non-melanoma skin cancer.

LED technology is based on photo biomodulation and dynamics rather than photo-thermolysis. Photo Therapeutics has recently developed the Omnilux Clear-U and Omnilux New-U, two OTC consumer products addressing the acne and skin rejuvenation markets. The company's home-use products are designed to deliver the same clinical results as their well established professional products. To augment the effects of the Omnilux OTC product line, Photo Therapeutics provides a diverse line of photoceuticals, which generate incremental recurring revenue per end user. Photo Therapeutics' LED technology is protected by 18 patents and 20 applications, which the company believes will restrict other parties from developing similar products.

About PhotoMedex

PhotoMedex offers a wide range of products and services across multiple specialty areas, including dermatology, urology, gynecology, orthopedics and other surgical specialties. PhotoMedex is a leader in the development, manufacturing and marketing of medical laser products and services. PhotoMedex also develops and markets products based on its patented, clinically proven Copper Peptide technology for skin health, hair care and wound care. PhotoMedex sells directly to dermatologists, plastic and cosmetic surgeons, spas and salons and through licenses with strategic partners into the consumer market, including a long-term worldwide license agreement with Neutrogena(R), a Johnson & Johnson company. ProCyte brands include Neova(R), Ti-Silc(R), VitalCopper(R), Simple Solutions(R) and AquaSante(R).

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on managements' current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The forward-looking statements contained in this release include statements about future financial and operating results and intentions of Photo Therapeutics Limited, Photo Therapeutics, Inc. and PhotoMedex, Inc., as well as the proposed acquisition, and its financing of Photo Therapeutics Limited and Photo Therapeutics, Inc. by PhotoMedex.

The following risks and factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: risk that the proposed acquisition and its proposed financing will not be consummated or will not be consummated during the fourth quarter of 2008; risk that Photo Therapeutics' business may not be integrated successfully with that of PhotoMedex; that there will be substantial costs related to the proposed acquisition and its financing; risk of subsequent default and forced repayment under the convertible notes to be issued in the proposed financing if any breach occurs related to these convertible notes; failure by PhotoMedex to receive from its stockholders the necessary proxy approval for the third-party investment to finance the acquisition; risks relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on strategic partners, ability to obtain financing and meet competition. Photo Therapeutics and PhotoMedex are under no obligation to (and expressly disclaim any such obligation to) update or alter these forward-looking statements, whether as a result of new information, future events or otherwise.

In connection with seeking stockholder approval of the proposed financing, PhotoMedex intends to file proxy materials and other relevant documents with the Securities and Exchange Commission. PhotoMedex's stockholders, and especially those reading this release, are urged to read the proxy statement (and any other relevant documents filed) with the SEC when they become available, because they will contain important information about the proposed financing. PhotoMedex will mail the definitive proxy statement to its stockholders, who may also obtain free copies of the final proxy statement, as well as PhotoMedex's other filings, without charge, at the SEC's Web site (www.sec.gov) when they become available. Copies of the filings may also be obtained without charge from the Company by directing a request to: 147 Keystone Drive, Montgomeryville, Pennsylvania, 18936, Attention: General Counsel.

The directors, executive officers and other members of management and employees of PhotoMedex may be deemed under SEC rules to be participants, through this press release, in the solicitation of proxies from stockholders in respect of the proposed financing. Information regarding PhotoMedex's directors and executive officers is available in the Company's 2007 Annual Report on Form 10-K, filed with the SEC on March 17, 2008, as amended by the Company's annual report on Form 10-K/A as filed with the SEC on May 8, 2008. Additional information regarding the interests of such potential participants will be included in the proxy statement and the other relevant documents filed with the SEC when they become available.

SOURCE: Photo Therapeutics, Inc. & PhotoMedex, Inc.

Lippert/Heilshorn & Associates, Inc. 
Kim Sutton Golodetz (investors), 212-838-3777 
Kgolodetz@lhai.com 
or 
Bruce Voss, 310-691-7100 
Bvoss@lhai.com 
or 
Photo Therapeutics, Inc. 
Sue D'Arcy, CEO, 760-607-0488 
or 
Photo Therapeutics Ltd. 
+44-161-925-5600 
info@phototherapeutics.com

About PhotoMedex

PhotoMedex offers a wide range of products and services across multiple specialty areas, including dermatology, urology, gynecology, orthopedics and other surgical specialties. PhotoMedex is a leader in the development, manufacturing and marketing of medical laser products and services. PhotoMedex also develops and markets products based on its patented, clinically proven Copper Peptide technology for skin health, hair care and wound care. PhotoMedex sells directly to dermatologists, plastic and cosmetic surgeons, spas and salons and through licenses with strategic partners into the consumer market, including a long-term worldwide license agreement with Neutrogena(R), a Johnson & Johnson company. ProCyte brands include Neova(R), Ti-Silc(R), VitalCopper(R), Simple Solutions(R) and AquaSante(R).

SAFE HARBOR STATEMENT

Some paragraphs of this press release, particularly those describing PhotoMedex' strategies, contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. While PhotoMedex is working to achieve those goals and strategies, actual results could differ materially from those projected in the forward-looking statements as a result of a number of factors, including difficulties in marketing its products and services, need for capital, competition from other companies and other factors, any of which could have an adverse effect on the business plans of PhotoMedex, its reputation in the industry or its expected financial return from operations. Factors such as these could have an adverse effect on PhotoMedex' results of operations. In light of significant uncertainties inherent in forward-looking statements included herein, PhotoMedex and its subsidiaries that it will be achieved should not regard the inclusion of such information as a representation.

SOURCE: PhotoMedex, Inc.

PhotoMedex, Inc.
Dennis McGrath, CFO
(215) 619-3287
info@photomedex.com
or
Investor Contacts:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz (Kgolodetz@lhai.com)
(212) 838-3777
Bruce Voss (Bvoss@lhai.com)
(310) 691-7100